Among genomic alterations deemed potentially targetable, whereby an approved targeted therapy exists in the same or other tumor types, statistically significant differences were observed between MTAP-loss versus MTAP-intact profiles (Fig. 3, Supplementary Fig. S2). The gene discussed is MTAP; the disease is neoplasm.